cdn mobile

Duterte to personally witness arrival of Sinovac vaccines on Feb. 28 — Palace

By: Krissy Aguilar - Reporter / @KAguilarINQ - Inquirer.net | February 26,2021 - 11:53 AM

VACCINE PRODUCTION A worker inspects a batch of vaccines produced at a Beijing factory built by Sinovac, one of 11 Chinese companies approved to carry out clinical trials of potential coronavirus vaccines, in this photo taken in September 2020. —AFP

MANILA, Philippines — President Rodrigo Duterte will personally witness the arrival of Sinovac Covid-19 vaccines donated by the Chinese government on Sunday, Malacañang has confirmed.

“It’s in his sched,” presidential spokesperson Harry Roque told INQUIRER.net in a text message on Friday.

In a previous online Palace briefing, Roque said the President wanted to personally welcome the arrival of the donated Sinovac vaccines out of  “utang an loob” (debt of gratitude).

China will donate some 600,000 doses of vaccines developed by Sinovac which Roque said will arrive on Sunday, Feb. 28.

This, after it finally secured an emergency use authorization from the Philippines’ Food and Drug Administration.

The Department of Health (DOH) and the National Task Force Against Covid-19 (NTF), meanwhile, said the rollout schedule of the donated vaccines remains on hold as immunization experts are still discussing the allocation of the 600,000 doses.

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

TAGS: Duterte, Sinovac
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.